Pharmacoepidemiologic and pharmacoeconomic aspects of angiotensinii receptor blockers consumption at the pharmaceutical market of Ukraine
DOI:
https://doi.org/10.24959/cphj.15.1344Keywords:
hypertension, angiotensin receptor blockers (ARBs II), economic accessibility, indicator of solvency adequacy, consumption, ATC/DDD-methodologyAbstract
The results of the analysis of the range, economic accessibility and consumption of angiotensin II receptor blockers (ARBs II) compared to ACE inhibitors within 2008-2013 have been considered. The choice of the optimal trade names (TN) has been substantiated according to the results of the “cost minimization” pharmacoeconomic analysis and the missed opportunities index. During the study period there was the increase in the range of ARBs II at the pharmaceutical market of Ukraine mainly due to foreign drugs. Drugs of ARBs II are characterized by lower availability for an average Ukrainian compared to ACE inhibitors. In the dynamics of the years the consumption volumes of ARBs II increased, but they were significantly inferior to the volume of ACE inhibitors consumption. During the research period the leaders of consumption were drugs of losartan, valsartan and candesartan, which were mostly generics. According to the results of the pharmacoeconomic analysis and the calculation of the missed opportunities some cheaper drugs of ARBs II have been identified. Using these drugs compared to more expensive ones allows to treat additionally a certain number of patients.
References
Вивчення споживання лікарських засобів за анатомо-терапевтично-хімічною класифі-кацією та встановленими добовими дозами (АТС/DDD – методологія) : метод. рек. / А. М. Морозов, Л. В. Яковлєва, А. В. Степаненко та ін. – Харків: Стиль-Издат. – 2013. – 34 с.
Громовик Б. П. Фармацевтичний маркетинг: теоретичні та прикладні засади / Б. П. Громовик, Г. Д. Гасюк, О. Р. Левицька. – Вінниця: Нова Книга, 2004. – 464 с.
Довгун С. С. Оценка стоимости и экономической доступности ноотропных препаратов, назначаемых больным с инсультом / С. С. Довгун // Современные проблемы науки и образования. – 2012. – № 2. – С. 33–39.
Мищенко О. Я. Фармакоэпидемиологическое исследование потребления антигипертензивных препаратов в Украине / О. Я. Мищенко, В. Ю. Адонкина, И. В. Чинуш // Фармацевтический журнал (Узбекистан). – 2013. – № 1. – С. 4–9.
Мнушко З. М. Система забезпечення доступності лікарських засобів / З. М. Мнушко, І. В. Тіманюк // Вісник фармації. – 2007. – № 1 (49). – С. 52–57.
Фармакоэкономика: учебное пособие для студентов вузов / Л. В. Яковлева, Н. В. Безде-тко, О. А. Герасимова и др. – Харьков: НФаУ: Золотые страницы. – 2007. –176 С.
Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial se-quential analyses of 147 020 patients from randomised trials / S. Bangalore, S. Kumar , J. Wetterslev, Messerli F. H. // BMJ. – 2011. – Vol. 342: d2234. doi:10.1136/bmj.d2234.
Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system / F. Turnbull, B. Neal, M. Pfeffer et al. // J. Hypertens. – 2007. – Vol. 25. – Р. 951-958.
Cardiovascular morbidity and mortality in the losartan intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol / B. Dahlof, R. B. Devereux, S. E. Kjeldsen et al. // Lancet. – 2002. – Vol. 23 (359). – P. 995-1003.
Comparative effectiveness of antihypertensive medication for primary prevention of cardiovascular disease: systematic review and multiple treatments meta-analysis / A. Fretheim, J. Odgaard-Jensen, O. Brørs [et al.] // BMC Medicine. – 2012 . – Vol. 10, № 33 – P.1-14.
Dahlof B. Prevention of stroke: new evidence European Heart Journal / B. Dahlof // European Heart Journal. – 2009. – Supplements 11 (Supplement F). – F33–F38.
Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study / T. Sawada, H. Yamada, B. Dahlof [et al.] // Eur. Heart J. – 2009. – Vol. 30. – P. 2461-2469.
Guidelines for the Management of Arterial Hypertension. 2013 ESH/ESC / K. Narkiewicz, J. Redon, A. Zanchetti [et al.] // Blood Press. – 2013. – Vol. 22, № 4. – P. 193-278.
Health Outcomes Associated With Various Antihypertensive Therapies Used as First-Line AgentsA Network Meta-analysis / B. M. Psaty, T. Lumley, C. D. Furberg [et al.] // JAMA. – 2003. – Vol. 289, №19. – P. 2534-2544.
Law M. R. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta–analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies / M. R. Law, J. K. Morris, N. J. Wald // BMJ. [Елект-ронний ресурс] – 2009. – Vol. 338. – Режим доступу: http://www.bmj.com/content/338/bmj.b1665.pdf%2Bhtml http://dx.doi.org/10.1136/bmj.b1665
The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial / H. Lithell, L. Hansson, I. Skoog [et al.] // J Hypertens. – 2003. – Vol. 21. – P. 875-886.
Downloads
Published
Issue
Section
License
Copyright (c) 2015 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
